Foreign investors followed after the group licensed voclosporin, originally developed to prevent organ-transplant rejections, from Edmonton's Isotechnika Pharma Inc., then did a reverse takeover of Isotechnika. Aurinia listed on Nasdaq in 2015 and had a US$1.9-billion market cap as of Friday.